ImpediMed reported a $3.5 million revenue in Q3 FY26, with reimbursement coverage in the US reaching 94.3%, supporting growth in heart health and weight management markets. New CEO Erik Anderson aims to accelerate commercial momentum and drive cash flow break-even.
- Q3 FY26 revenue of $3.5 million, down 10% quarter-on-quarter
- US reimbursement coverage expands to 94.3% of lives
- Initial sales in Heart Health and Weight Management markets
- Annual Recurring Revenue steady at $14.1 million
- New CEO Erik Anderson appointed to boost US growth
Reimbursement Coverage Fuels US Market Expansion
ImpediMed Limited (ASX:IPD) has pushed its US reimbursement coverage for the SOZO platform to 94.3% of the population, now covering 328 million lives. This marks a meaningful increase from the 92.8% coverage reported just a quarter ago, with 37 states surpassing 95% coverage; a jump of 17 states since December 2025. The broadening reimbursement footprint is critical in driving new customer acquisition and reactivating existing accounts, underpinning the company’s commercial growth in breast cancer-related lymphoedema (BCRL), heart health, and body composition markets.
The company currently has 617 SOZO units installed across leading US hospitals, supported by Master Services Agreements with 27 major Integrated Delivery Networks. These agreements streamline IT approvals and accelerate access to hospital systems, positioning ImpediMed to capitalise on opportunities across multiple indications.
Reimbursement expansion has been a consistent theme for ImpediMed, following earlier gains where coverage reached over 301 million lives, as documented in the expanded insurance reimbursement announcement last year.
Early Sales in Heart Health and Weight Management
Commercialisation efforts for SOZO Pro in the heart health market are underway, with initial sales recorded during the quarter. SOZO Pro is the only FDA-cleared bioimpedance spectroscopy (BIS) device approved for patients with cardiac implantable devices, a niche that addresses the urgent need to reduce hospital readmissions for the 6.7 million US heart failure patients.
The US outpatient heart failure fluid monitoring market is estimated at US$600 million, and SOZO Pro’s Medicare National Coverage Determination; covering approximately 75% of heart failure patients on Medicare; provides a solid reimbursement foundation. Sales activities have also commenced in the weight management sector, where SOZO’s precise body composition monitoring complements GLP-1 therapies, offering clinicians a more nuanced measure of treatment success beyond weight alone.
Financial Performance and Operational Efficiency
ImpediMed posted $3.5 million in revenue for Q3 FY26, down 10% from the previous quarter, primarily due to distributor restocking in the rest of the world (ROW) markets and a stronger Australian dollar. On a constant currency basis, US revenue actually increased by 2%, reflecting underlying growth in the core market. The company sold 36 SOZO units in the quarter, with 30 units sold in the US compared to 19 in Q2 FY26.
Core Business Total Contracted Value (TCV) rose to $5.4 million, up from $4.1 million in the prior quarter, while Annual Recurring Revenue (ARR) stood at $14.1 million, or $14.9 million on a constant currency basis. These figures highlight steady subscription-based revenue streams, critical for long-term sustainability.
Cash receipts totalled $3.3 million, against net operating cash outflows of $4.5 million. Staff costs, the largest expense line at $4.5 million, declined $0.8 million quarter-on-quarter due to currency effects and ongoing cost reduction programs. The cash balance at quarter-end was $12.7 million, providing 2.9 quarters of operating runway. The company’s fully drawn US$15 million loan facility carries a 9.5% plus SOFR interest rate and matures in 2030.
New CEO Erik Anderson to Accelerate US Growth
On 7 April 2026, Erik Anderson took the helm as Managing Director and CEO, bringing deep US healthcare expertise from his previous role as Division President at Hologic’s Breast and Skeletal Health business. His appointment signals a strategic push to strengthen health system engagement, accelerate revenue growth, and steer ImpediMed toward cash flow break-even.
Anderson’s background in hospital procurement, reimbursement, and clinical adoption aligns with ImpediMed’s ambition to scale its SOZO platform across multiple clinical indications. His leadership is expected to build on the company’s recent commercial momentum, including the launch of Heart Health and Weight Management sales teams and the expanded CEO appointment to accelerate US growth announced earlier.
Investors will be watching how Anderson’s operational focus translates into market traction and improved cash flow metrics, especially as the company recently secured a A$15.2 million capital raise and initiated cost-cutting measures aimed at reaching operating cash flow breakeven by FY28.
Bottom Line?
ImpediMed’s expanding US reimbursement and new CEO appointment set the stage for accelerated commercialisation, but sustaining momentum while managing cash burn remains critical.
Questions in the middle?
- Can new CEO Erik Anderson translate reimbursement gains into sustained revenue growth?
- How will the nascent Heart Health and Weight Management sales efforts scale amid competitive pressures?
- What impact will currency fluctuations and cost reduction programs have on the path to cash flow break-even?